Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Debt (2018 - 2022)

Historic Non-Current Debt for Sutro Biopharma (STRO) over the last 5 years, with Q4 2022 value amounting to $3.8 million.

  • Sutro Biopharma's Non-Current Debt fell 7603.89% to $3.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was $3.8 million, marking a year-over-year decrease of 7603.89%. This contributed to the annual value of $3.8 million for FY2022, which is 7603.89% down from last year.
  • As of Q4 2022, Sutro Biopharma's Non-Current Debt stood at $3.8 million, which was down 7603.89% from $6.8 million recorded in Q3 2022.
  • In the past 5 years, Sutro Biopharma's Non-Current Debt ranged from a high of $24.7 million in Q1 2021 and a low of $3.8 million during Q4 2022
  • For the 5-year period, Sutro Biopharma's Non-Current Debt averaged around $14.6 million, with its median value being $12.1 million (2018).
  • Per our database at Business Quant, Sutro Biopharma's Non-Current Debt skyrocketed by 34383.64% in 2020 and then tumbled by 7603.89% in 2022.
  • Quarter analysis of 5 years shows Sutro Biopharma's Non-Current Debt stood at $10.0 million in 2018, then dropped by 11.24% to $8.9 million in 2019, then skyrocketed by 176.53% to $24.5 million in 2020, then crashed by 35.88% to $15.7 million in 2021, then crashed by 76.04% to $3.8 million in 2022.
  • Its Non-Current Debt stands at $3.8 million for Q4 2022, versus $6.8 million for Q3 2022 and $9.8 million for Q2 2022.